Ciprofloxacin: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 9: | Line 9: | ||
** MIC of 1 previously reported as susceptible but had reports of reduced susceptibility in practice |
** MIC of 1 previously reported as susceptible but had reports of reduced susceptibility in practice |
||
** New cutoff is 0.5 for susceptibility |
** New cutoff is 0.5 for susceptibility |
||
== Safety == |
|||
* Similar to other fluoroquinolones |
|||
* QTc prolongation may not be as much of a clinical concern at usual doses[[CiteRef::liu2026th]] |
|||
[[Category:Fluoroquinolones]] |
[[Category:Fluoroquinolones]] |
||
Latest revision as of 16:27, 6 April 2026
Background
- Fluoroquinolone antibiotic with antipseudomonal activity
- Inhibits CYP1A2
Clinical Breakpoints
- For the Enterobacteriaceae changed recently
- MIC of 1 previously reported as susceptible but had reports of reduced susceptibility in practice
- New cutoff is 0.5 for susceptibility
Safety
- Similar to other fluoroquinolones
- QTc prolongation may not be as much of a clinical concern at usual doses1
References
- ^ Weber Liu, Hugh G Dickson, Hany Dimitri, Yashodha Shankar Pani, Jayanathi Ramanathan, Dana West, Sarah Tima, Winston Thai. The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting. Journal of Antimicrobial Chemotherapy. 2026;81(3). doi:10.1093/jac/dkag020.
